WX-UK1 | CAS#220355-63-5 | uPA inhibitor

MedKoo Cat#: 464728 | Name: WX-UK1

Description:

WARNING: This product is for research use only, not for human or veterinary use.

WX-UK1 is a novel potent urokinase-type plasminogen activator (uPA) inhibitor, also inhibiting TMPRSS2 against SARS-COV-2.

Chemical Structure

WX-UK1

CAS#220355-63-5

Theoretical Analysis

MedKoo Cat#: 464728

Name: WX-UK1

CAS#: 220355-63-5

Chemical Formula: C32H47N5O5S

Exact Mass: 613.3298

Molecular Weight: 613.82

Elemental Analysis: C, 62.62; H, 7.72; N, 11.41; O, 13.03; S, 5.22

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

WX-UK1; WXUK1; WX UK1; UKI-1; UKI1; UKI 1; UKI-1C; UKI1C; UKI 1C;

IUPAC/Chemical Name

ethyl (S)-4-(3-(3-carbamimidoylphenyl)-2-((2,4,6-triisopropylphenyl)sulfonamido)propanoyl)piperazine-1-carboxylate

InChi Key

ISJSHQTWOHGCMM-NDEPHWFRSA-N

InChi Code

InChI=1S/C32H47N5O5S/c1-8-42-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34)35-43(40,41)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7/h9-11,16,18-22,28,35H,8,12-15,17H2,1-7H3,(H3,33,34)/t28-/m0/s1

SMILES Code

O=C(N1CCN(C([C@@H](NS(=O)(C2=C(C(C)C)C=C(C(C)C)C=C2C(C)C)=O)CC3=CC=CC(C(N)=N)=C3)=O)CC1)OCC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 613.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tervonen TA, Belitškin D, Pant SM, Englund JI, Marques E, Ala-Hongisto H, Nevalaita L, Sihto H, Heikkilä P, Leidenius M, Hewitson K, Ramachandra M, Moilanen A, Joensuu H, Kovanen PE, Poso A, Klefström J. Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion. Oncogene. 2016 Apr 7;35(14):1832-46. doi: 10.1038/onc.2015.248. Epub 2015 Jul 13. PMID: 26165838. 2: Froriep D, Clement B, Bittner F, Mendel RR, Reichmann D, Schmalix W, Havemeyer A. Activation of the anti-cancer agent upamostat by the mARC enzyme system. Xenobiotica. 2013 Sep;43(9):780-4. doi: 10.3109/00498254.2013.767481. Epub 2013 Feb 4. PMID: 23379481. 3: Schmitt M, Harbeck N, Brünner N, Jänicke F, Meisner C, Mühlenweg B, Jansen H, Dorn J, Nitz U, Kantelhardt EJ, Thomssen C. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn. 2011 Jul;11(6):617-34. doi: 10.1586/erm.11.47. PMID: 21745015. 4: Zengel P, Ramp D, Mack B, Zahler S, Berghaus A, Muehlenweg B, Gires O, Schmitz S. Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis. BMC Cancer. 2010 Mar 11;10:92. doi: 10.1186/1471-2407-10-92. PMID: 20222943; PMCID: PMC2841144. 5: Setyono-Han B, Stürzebecher J, Schmalix WA, Muehlenweg B, Sieuwerts AM, Timmermans M, Magdolen V, Schmitt M, Klijn JG, Foekens JA. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost. 2005 Apr;93(4):779-86. doi: 10.1160/TH04-11-0712. PMID: 15841327. 6: Ertongur S, Lang S, Mack B, Wosikowski K, Muehlenweg B, Gires O. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer. 2004 Jul 20;110(6):815-24. doi: 10.1002/ijc.20192. PMID: 15170662. 7: Schuh T, Besch R, Braungart E, Flaig MJ, Douwes K, Sander CA, Magdolen V, Probst C, Wosikowski K, Degitz K. Protease inhibitors prevent plasminogen- mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis. Biol Chem. 2003 Feb;384(2):311-5. doi: 10.1515/BC.2003.035. PMID: 12675525.